Cardiff Oncology, Inc.
NASDAQ:CRDFBiotechnology
+$0.03 today
- Market cap
- $65.27M
- Beta
- 1.38
- P/E (TTM)
- -1.8
- EPS (TTM)
- -$0.65
Volume 0.86M
Average 1.05M
CRDF Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
Cardiff Oncology, Inc.NASDAQ: CRDF
Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026
Selling, general & admin growth accelerates
Q1 FY2026 selling, general & admin of $6.13M rose 52.6% year over year, ahead of the +27.1% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 104.5% from the prior quarter. Over 3 fiscal years it compounded at +2.6% a year.
Context
- Selling, general & admin amounted to 2398.7% of revenue in FY2025, up 571.1 pp from a year earlier.
- Selling, general & admin increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether selling, general & admin reaches the consensus estimate from 5 analysts of $8.91M (-37.3%) for the fiscal year ending Dec 2026, a slowdown from the +14.0% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $6.13M+104.5% QoQ
- Last fiscal yearDec 2025
- $14.22M+14.0% YoY
- LTMMar 2026
- $13.02M+27.1% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +52.6% | — | — |
| 1 year | +14.0% | -37.3% | -51.3 pp |
| 3-year CAGR | +2.6% | -18.1% | -20.6 pp |
| 5-year CAGR | +258.6% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 14.22M USD
- Year-over-year change
- +14.0%
- 4-year CAGR
- +4.7%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 14.22M | +14.0% |
| FY2024 | 2024-12-31 | 12.48M | -4.3% |
| FY2023 | 2023-12-31 | 13.04M | -1.0% |
| FY2022 | 2022-12-31 | 13.18M | +11.3% |
| FY2021 | 2021-12-31 | 11.84M | — |
Selling, General & Admin vs competitors
How CRDF compares with its peers on the latest reported figures
- Peers report in different currencies, so selling, general & admin is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +27.1% is the highest of 9, against a peer median of -5.0%.
- Selling, general & admin amounts to 2479.6% of revenue for CRDF, versus a peer median of 599.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $34.83M USD | -4.4% | -11.4% | 1952.5% | |
| LTM Mar 2026 | $22.56M USD | +1.9% | +16.6% | — | |
| LTM Mar 2026 | $19.01M USD | -17.8% | -9.7% | 599.8% | |
| LTM Mar 2026 | CHF 16.11M CHF | -3.8% | -12.0% | — | |
| LTM Mar 2026 | $15.52M USD | -5.5% | -6.6% | — | |
ELTXElicio Therapeutics, Inc. | LTM Mar 2026 | $13.7M USD | +20.3% | +31.5% | — |
| LTM Mar 2026 | $13.02M USD | +27.1% | +2.6% | 2479.6% | |
| FY2025 | €11M EUR | -7.8% | -8.7% | 394.7% | |
| LTM Mar 2026 | $10.95M USD | -28.8% | +14.3% | — | |
| Peer median (excluding CRDF) | — | -5.0% | -7.7% | 599.8% | |
Competitors are the stored peer set for CRDF. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 359K | 386K | 488K | 683K | 593K |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 359K | 386K | 488K | 683K | 593K |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Research & Development | 17.38M | 27.11M | 32.86M | 36.85M | 35.33M |
| Selling, General & Admin | 11.84M | 13.18M | 13.04M | 12.48M | 14.22M |
| Operating Expenses | 29.21M | 40.29M | 45.9M | 49.33M | 49.55M |
| Depreciation & Amortization | 451K | 236K | 398K | 404K | 904K |
| EBITDA | (27.84M) | (38.47M) | (41.04M) | (45.03M) | (44.95M) |
| EBITDA Margin | -7754.9% | -9965.8% | -8410.5% | -6592.5% | -7579.6% |
| Operating Income | (28.86M) | (39.9M) | (45.41M) | (48.65M) | (48.96M) |
| Operating Margin | -8037.6% | -10337.3% | -9305.7% | -7123.1% | -8256.3% |
| Interest Income | 264K | 1.58M | 4.07M | 3.26M | 3.1M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 564K | 1.2M | 3.97M | 3.22M | 3.11M |
| Income Before Tax | (28.29M) | (38.7M) | (41.44M) | (45.43M) | (45.85M) |
| Pre-Tax Margin | -7880.5% | -10026.9% | -8492.0% | -6651.7% | -7732.0% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (28.29M) | (38.7M) | (41.44M) | (45.43M) | (45.85M) |
| Net Margin | -7880.5% | -10026.9% | -8492.0% | -6651.7% | -7732.0% |
| EPS (Basic) | (0.73) | (0.89) | (0.93) | (0.95) | (0.69) |
| EPS (Diluted) | (0.73) | (0.89) | (0.93) | (0.95) | (0.69) |
| Weighted Avg Shares | 39.03M | 43.6M | 44.68M | 47.65M | 66.84M |
| Weighted Avg Shares (Diluted) | 39.03M | 43.6M | 44.68M | 47.65M | 66.84M |
Cardiff Oncology, Inc.
NASDAQ:CRDF
Intrinsic Alpha fair value
Locked
Current Price
$0.84
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.